Changes in Inflammatory Biomarkers When Switching from Three-Drug Regimens to Dolutegravir Plus Lamivudine in People Living with HIV
- 1 December 2022
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 38 (12), 881-883
- https://doi.org/10.1089/aid.2022.0115
Abstract
It is not clear if there is a difference between 3-drug regimens (3DR) and 2-drug regimens (2DR) in terms of suppression of chronic inflammation. We compared CRP, CD4+/CD8+ ratio, lipid proliges measured in daily clinical practice before and after the switch to dolutegravir plus lamivudine (DTG/3TC) to examine the difference in the anti-inflammatory effect of 3DR and 2DR. In this single-center, retrospective, observational study, individuals who were on abacavir/lamivudine/dolutegravir (ABC/3TC/DTG), Tenofovir alafenamide/emtricitabine (TAF/FTC) plus DTG, or bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) prior to switching to DTG/3TC, were eligible. A total of 119 individuals were enrolled in the study. The median (IQR) time since diagnosis of HIV infection was 12 (7-16) years. Overall, inflammation markers such as CD4+/CD8+ ratio, CD4+, CRP and lipid profiles did not change. Analysis of only individuals who switched from ABC/3TC/DTG, TAF-based regimens also showed no significant changes in inflammatory markers. Since viremia raises inflammatory markers, differences in antiviral efficacy may make a difference in the suppression of chronic inflammation but in conclusion, we did not find any change in inflammatory markers by changing from 3DR to 2DR in daily clinical practice.Keywords
This publication has 8 references indexed in Scilit:
- Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized TrialClinical Infectious Diseases, 2022
- Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature ReviewOpen Forum Infectious Diseases, 2022
- Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized TrialClinical Infectious Diseases, 2022
- Immunomodulatory and Anti-Inflammatory Strategies to Reduce Comorbidity Risk in People with HIVCurrent HIV/AIDS Reports, 2020
- Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV SuppressionClinical Infectious Diseases, 2016
- The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levelsAIDS, 2015
- Systemic Effects of Inflammation on Health during Chronic HIV InfectionImmunity, 2013
- Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV InfectionPLoS Medicine, 2008